![FDA Approves Foundation Medicine's FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics | Business Wire FDA Approves Foundation Medicine's FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics | Business Wire](https://mms.businesswire.com/media/20171130006320/en/627352/5/F1CDx_Image.jpg)
FDA Approves Foundation Medicine's FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics | Business Wire
![Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA - ScienceDirect Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1525157817305275-gr1.jpg)
Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA - ScienceDirect
![FDA Approves Foundation Medicine's FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics | Business Wire FDA Approves Foundation Medicine's FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics | Business Wire](https://mms.businesswire.com/media/20171130006320/en/627351/5/FMI_lockup%C2%AE_left_fire_RGB300ppi_For_BW.jpg)
FDA Approves Foundation Medicine's FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics | Business Wire
![Concordance analysis of microsatellite instability status between polymerase chain reaction based testing and next generation sequencing for solid tumors | Scientific Reports Concordance analysis of microsatellite instability status between polymerase chain reaction based testing and next generation sequencing for solid tumors | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-021-99364-z/MediaObjects/41598_2021_99364_Fig1_HTML.png)
Concordance analysis of microsatellite instability status between polymerase chain reaction based testing and next generation sequencing for solid tumors | Scientific Reports
![Workflow for TMB assessment using the FoundationOne CDx assay [63].... | Download Scientific Diagram Workflow for TMB assessment using the FoundationOne CDx assay [63].... | Download Scientific Diagram](https://www.researchgate.net/publication/334081089/figure/fig2/AS:774610417090560@1561692923137/Workflow-for-TMB-assessment-using-the-FoundationOne-CDx-assay-63-ExAC-Exome.png)
Workflow for TMB assessment using the FoundationOne CDx assay [63].... | Download Scientific Diagram
![U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for EGFR Therapeutics Targeting Exon 19 Deletions or Exon 21 Substitutions in Non-Small Cell Lung Cancer | Business Wire U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for EGFR Therapeutics Targeting Exon 19 Deletions or Exon 21 Substitutions in Non-Small Cell Lung Cancer | Business Wire](https://mms.businesswire.com/media/20220317005345/en/794671/22/FMI_horizontal-slate_%282%29.jpg)
U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for EGFR Therapeutics Targeting Exon 19 Deletions or Exon 21 Substitutions in Non-Small Cell Lung Cancer | Business Wire
![Next generation sequencing‐based gene panel tests for the management of solid tumors - Nagahashi - 2019 - Cancer Science - Wiley Online Library Next generation sequencing‐based gene panel tests for the management of solid tumors - Nagahashi - 2019 - Cancer Science - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/5e217831-bca0-49b3-9803-94f23381c34a/cas13837-fig-0003-m.jpg)
Next generation sequencing‐based gene panel tests for the management of solid tumors - Nagahashi - 2019 - Cancer Science - Wiley Online Library
Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors | PLOS ONE
![FDA Approves Foundation Medicine's FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics | Business Wire FDA Approves Foundation Medicine's FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics | Business Wire](https://mms.businesswire.com/media/20171130006320/en/627350/4/Lab_Image_for_Press_Kit.jpg)
FDA Approves Foundation Medicine's FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics | Business Wire
![FDA Approves Foundation Medicine's FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics | Business Wire FDA Approves Foundation Medicine's FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics | Business Wire](https://mms.businesswire.com/media/20171130006320/en/627349/5/FMI_Exterior_for_Press_Kit.jpg)
FDA Approves Foundation Medicine's FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics | Business Wire
![JPM | Free Full-Text | Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe JPM | Free Full-Text | Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe](https://www.mdpi.com/jpm/jpm-12-00072/article_deploy/html/images/jpm-12-00072-g001.png)